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Background: To characterize single nucleotide polymorphisms (SNPs) within the promoter region of the estrogen
receptor beta (ERβ) gene and to analyze the association of ERβ SNPs with susceptibility to breast cancer. Genotype
frequencies of five SNPs (rs3020449, rs3020450, rs2987983, rs1271572 and rs1887994) in the promoter region of the ERβ
gene in 873 women with breast cancer, 645 women with fibroadenoma and 700 healthy women were determined
using an allele-specific tetra-primer polymerase chain reaction (PCR). Kaplan-Meier survival analysis was performed to
evaluate the association of selected rs1271572 with prognosis in breast cancer. Electrophoretic mobility-shift assays
were conducted to explore the binding of SNP rs1271572 containing probes to transcriptional factor Ying Yang 1 (YY1).
Results: Women with the homozygous TT genotype of rs1271572 had a significantly higher risk in developing breast
cancer. Breast cancer patients with the TT genotype of rs1271572 had lower five-year survival rates than those with
other genotypes and were more likely to suffer brain metastases. The rs1271572 G→T SNP abrogated YY1 binding and
reduced the transcription activity of the promoter 0 N in the ERβ gene in vitro.
Conclusions: TT genotype of rs1271572 is associated with increased risk for breast cancer in Chinese women and is
associated with unfavored prognosis in Chinese breast cancer patients. TT genotype of rs1271572 inhibited expression
of ERβ gene by down regulating transcriptional activity of the promoter 0 N in the ERβ gene. Our data revealed that
the TT genotype of rs1271572 resulted in loss of the YY1 binding site and reduced the transcription activity of the
promoter 0 N in the ERβ gene.
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Breast cancer is a worldwide health problem among
women and causes an estimated 450,000 deaths annually
[1]. In China,breast cancer is the most prevalent cancer
in women and ranks as the 6th leading cause of death in
Chinese women [2,3]. Single nucleotide polymorphisms
(SNPs) are the most frequent sequence variations in the
human genome [4]. Evidence from population studies* Correspondence: luoxd2005@163.com; jiangjun8086@126.com
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ERβ (estrogen receptor β) plays a significant role in
suppressing breast cancer cell proliferation [5] and acts as
a negative modulator of ERα activity [6]. ERβ expression
declines during breast tumorigenesis [7]; however, the
mechanisms of ERβ down-regulation in breast cancer
remain unclear. A few studies have reported an association
between genotypic polymorphisms of ERβ with breast
cancer susceptibility [8-10]. However, most of the population
studies were performed in Europeans and Americans and
the results have been inconsistent [11,12]. Currently, no
such association studies have been performed in the
Chinese populations.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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whereas SNPs in the gene promoter can modify gene
expression levels [13,14]. Hirata et al. reported that
transcription of the human ERβ gene occurs from at
least two different promoters, named promoter 0 N and
promoter 0 K [15]. Further studies have shown that
transcripts from promoter 0 N are more prominent than
those from promoter 0 K in normal breast epithelial
cells and in a panel of breast cancer cell lines [16]. Based
on a bioinformatics analyses of all the polymorphisms
identified in the putative promoter of the ERβ gene, we
selected five SNPs near the transcription start site of
promoters 0 N of the ERβ gene (rs3020449 C/T, rs3020450
A/G, rs2987983C/T, rs1271572 G/T and rs1887994 G/T)
as targets for the present study and characterized the
five SNPs in the putative promoter of the ERβ gene in a
population of Chinese women from southwest China. We
also investigated whether an association exists between
breast cancer risk and SNP rs1271572 G/T in the ERβ




The study was approved by the Ethical Committee of the
Third Military Medical University and the Hospital Clinic
Ethics Review Committee. Written informed consent was
obtained from all participants involved in the study.
Study subjects
From January 2002 to December 2004, all the sporadic
breast cancer patients with invasive ductal carcinoma who
were selected to undergo surgery and adjuvant chemo-
therapy (cyclophosphamide 100 mg/m2 D1, doxorubicin
30 mg/m2 D1,8, and fluorouracil 500 mg/m2 D1,8; all
drugs given intravenously (IV) every 28 days, for a total of
six cycles) were eligible for the present study. Diagnosis
was confirmed using histologic examination of all speci-
mens. Exclusion criteria included pregnancy, non-surgical
candidates, patients unwilling to undergo treatment,
patients with a family history of breast cancer, patients
with congestive heart failure, ischemic heart disease,
other malignancies, severe hepatic or renal dysfunction,
altered mental status or patients who were over 70 years
old. The patients (n = 873; median age 45.8 ± 12.5 years,
range 22–70 years) were diagnosed at our Breast Disease
Center at the Third Military Medical University and at the
Affiliated Hospital of North Sichuan Medical College,
China. Eighteen of the 873 patients were excluded because
tetra-primer ARMS PCR failed. Since it was difficult to
obtain a sufficient number of normal breast tissue samples,
we chose to use tissues from fibroadenoma patients
as controls in a scoring system for ERβ expression.
The patients with fibroadenomas (n = 645; medianage 44.5 ± 10.6 years, range 18–69 years) were enrolled after
receiving appropriate informed consent. Fibroadenoma
is not a premalignant disease. 700 healthy female blood
donors (median age 41.5 ± 12.1 years, range 20–59 years)
with no history of any type of cancer or any relatives
with a history of breast cancer were recruited for the
present study as the second control group. The average
age of incidence of breast cancer is 45.8. This is one of the
criteria for selecting 700 cases of healthy controls.
According to regulations in China, people over 60 years of
age are not allowed to donate blood. Other factors in
control groups are matched with those in breast cancer
groups. In addition, the control subjects (patients with
fibroadenomas and healthy female blood donors) should
be drawn from the same population.
Bioinformatics analyses of the ERβ gene promoter
Our hypothesis is that SNPs in the promoter of the
ERbeta gene could affect its expression, which could be a
risk factor for breast cancer. Thus, we searched SNPs near
the promoter of ER beta. The transcription of the human
ERβ gene occurs from at least two different promoters,
promoter 0 N and promoter 0 K [15]. AS transcripts from
promoter 0 N were found to be more prominent than
those from promoter 0 K [15,16], we referred to the NCBI
database of known SNPs (http://www.ncbi.nlm.nih.gov/
snp/?term=ESR2, NCBI36/hg18) and selected five SNPs
from the putative promoter region near the transcription
start site of promoters (as shown in Additional file 1:
Figure S1) 0 N: rs3020449, rs3020450, rs2987983, rs1271572
and rs1887994 that were also studied by others [8,17-20].
Tetra-primer ARMS PCR
Genomic DNA from blood was isolated using a Wizard
Genomic DNA Purification Kit (Promega, USA) according
to the manufacturer’s instructions. The genomic DNA
was resuspended in 50 μL PCR buffer (GoTaq buffer,
Promega, USA), containing 0.5% Tween 20, 10 mAnson
units proteinase K (Merck, Germany) and incubated at
50°C overnight. The mixture was then heated for 10 min
at 95°C to inactivate the enzyme.
Allelic-specific tetra-primer amplification was performed
on the genomic DNA using a tetra-primer ARMS PCR
approach. Each PCR reaction was carried out in a total
volume of 10 μl, containing 30 ng of template DNA, 10
pmol of each inner primer, 1 pmol of each outer primer,
200 μM dNTP, and 0.5 units Go Taq polymerase (Promega,
USA). The reaction was overlaid with 5 μl of liquid paraffin.
The PCR cycling conditions for the detection of rs3020449
and rs3020450 were as follows: 95°C for 5 min, then
33 cycles of 95°C for 1 min, 61°C for 1 min, and 72°C
1 min, followed by 72°C for 5 min. For detecting
rs2987983, rs1271572 and rs1887994, the following cycling
conditions were utilized: 94°C for 5 min, 33 cycles of 94°C
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by 72°C for 5 min. PCR products were mixed with
2 μl of loading buffer and analyzed using 3% agarose
gel electrophoresis. The primers used for the PCR reaction
are listed in Additional file 2: Table S1. Allelic-specific
PCR product sizes were 353/250 bp (C/T) for SNP
rs3020449, 209/ 419 bp (A/G) for rs3020450, 276/164 bp
(C/T) for rs2987983, 276/133 bp (G/T) for rs1271572 and
229/418 bp (G/T) for SNP rs1887994. The genotyping
success rate was 97.8%. As a quality control for genotyping,
in each PCR reaction two previously characterized DNA
samples representing the heterozygous and the two
homozygous genotypes were analyzed in addition to the
unknown samples. Genotyping was performed blinded
without knowledge of the patients’ clinical data.
Cell culture
Human breast cancer cell lines MDA-MB-231, MCF-7,
MDA-MB-468, BT-549 and ZR75-30 (purchased from the
American Type Culture Collection, Manassas, VA, USA),
were maintained in modified MEM media supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine
and 20 lg/mL gentamycin. Cell cultures were grown at 37°C
in a humidified atmosphere with 5% CO2 in a Hereaus
CO2 incubator. To culture primary breast cancer cells,
clinical resected breast cancer specimens were sheared to
fractions, digested with trypsin/EDTA (0.05%/0.02% in
PBS) for 20–30 min at 37°C, followed by three washes
with culture medium containing 10% FBS. Following
filtration through 56 μm gauze, the single-cell suspension
was then counted and seeded in six-well plates. After
one week, the cancer cell clones were selected for culture.
The primary breast cancer cells were identified using
pathological examination.
Plasmid construction, YY1 knock down, transient
transfection and luciferase reporter assays
The cDNA of promoter 0 N plus the partial upstream
sequence of the intron up to the ATG transcriptional
starting site in exon 1 (ESR2-0 N + −2316 ~ +1) and
the cDNA of promoter 0 K plus the partial upstream
sequence of the intron up to the ATG of exon 1
(ESR2-0 K + −1868 ~ +1) (as shown in Additional file 3:
Figure S2) were amplified from genomic DNA and the
corresponding fragments were then subcloned into the
Sac I and Hind III sites of the luciferase reporter vector,
pGL3-basic (Promega) [10], to create pESR2-0 N-G-Luc
(containing the G allele of rs1271572), pESR2-0 N-T-Luc
(containing the T allele of rs1271572) and pESR2-0 K-Luc
vectors. All vectors were confirmed by sequencing. To
specifically knock down YY1, YY1-specific siRNA oligo
sequences were used as follows: the siRNA target
sequence: GACGACGACTACATTGAACAA; the siRNA
sense: oligo r (CGACGACUACAUUGAACAA)dTdT; andthe siRNA antisense oligo: r(UUGUUCAAUGUAGUCG
UCG) dTdC.
Transient transfection was performed using FuGENE 6
reagent (Roche Applied Science) as described previously
[5]. In brief, breast cancer cells growing from indicated
cell lines or primary cultures were seeded into a 24-well
plate at a density of 1 × 105 cells/well or in 6-well plate at
a density of 1× 106 cells/well and were allowed to grow for
24 hours. 1.0 μg of reporter gene constructs pRL alone or
in combination with 5 nM YY1-specific siRNA oligos
were transiently transfected into these cells. 48 hours post
transfection, cells were rinsed with PBS and then lysed in
1× passive lysis buffer. Luciferase activity was determined
using a dual-luciferase reporter assay kit (Promega). The
ratio of firefly luciferase activity was normalized to Renilla
luciferase activity. The pGL3-control (Promega) was also
used as an additional control in these experiments.
Electrophoretic mobility-shift assay (EMSA)
Nuclear extract preparation and EMSAs were performed
as previously described [21] with slight modifications. In
brief, a thawed breast cancer cell pellet was first lysed in
ice-cold Buffer A (25 mM Tris–HCl, pH 7.5, 50 mM
KCl, 2 mM MgCl2, 5 mM dithiothreitol, and inhibitors
of phosphatases). After removing supernatants by centri-
fugation, buffer C (20 mM Tris–HCl, pH 7.5, 0.42M
NaCl, 1.5 mM MgCl2, 25% sucrose, 1 mM dithiothreitol,
and inhibitors of phosphatase) was added and gently
shaked for 30 min at 0°C. The supernatants were collected
and concentration of nuclear proteins was measured. The
oligonucleotides probes containing the two SNP alleles of
the human ERβ gene promoter region were as follows:
probe–rs1271572G (with the G allele), 5’-TGTGACAC
TGGGGGGGTCTCACAATGGCCT-3’; and probe–
rs1271572T (with the T allele), 5’-TGTGACACTGGGGG
GTTCTCACAATGGCCT-3’. The double-stranded
DNA probes were end-labeled with γ- 32P ATP and T4-
polynucleotide kinase (Promega). The nuclear protein-
DNA binding reaction was performed at 37°C for 20 min
in a total volume of 20 μl containing 10 μg nuclear extract
proteins and 0.2 ng of labeled double probes or a 50-fold
non-labeled competitor probe. The DNA-protein com-
plexes were resolved by electrophoresis through a 4%
poly-acrylamide gel. Gels were dried and the labeled
complexes were detected by autoradiography.
Immunohistochemistry
The breast specimens from patients with breast cancer or
fibroadenoma were fixed in a 0.1 M phosphate-buffered
10% formaldehyde solution for 24 h, dehydrated, and
embedded in paraffin (5 μm sections were used). The
primary antibody dilutions found to be optimal for this
study were 1:500 for ERβ (mAb, Chemicon International).
All data on ERα, PgR, and HER2 status were retrieved
Chen et al. Journal of Biomedical Science 2013, 20:32 Page 4 of 12
http://www.jbiomedsci.com/content/20/1/32from pathology reports performed by a pathologist
(positives are defined when more than 10% of tumor cells
are stained). The specificity of the immunohistochemical
procedures was checked using negative and positive
control sections.
A scoring system for ERβ expression in the tissues was
used as follows: no staining (0 points), weak staining
(1 point, staining in less than 20% of tumor cells), low
staining (2 points, staining in 21–40% of tumor cells),
medium staining (3 points, staining in 41–60% of tumor
cells), and high staining (4 points, staining in over 61%
of tumor cells) tissues. Each tissue has three different
slides. The typical slice including the center and edge of
cancer were chosen and total positive cancer cell rate was
calculated as the score for that tissue by a pathologist.
A total of 1,483 immunohistochemically stained ERβ
tissues (from 628 fibroadenoma and 855 breast cancer)
underwent central review.
Statistical analyses
The allelic and genotypic frequencies for each SNP were
calculated, and deviation from the Hardy–Weinberg
equilibrium was estimated using a χ2 test. The differences
in allelic and genotypic frequencies between the breast
cancer group, the fibroadenoma group, and the healthy
blood donor group were estimated and statistical tests
for association (95% confidence interval [CI]) and for
significance were performed using SPSS (version 14)
for Windows (SPSS, Inc., Chicago, IL) and SHEsis
(http://analysis.bio-x.cn/myAnalysis.php). The results were
considered to be significant when p < 0.05.
Cause-specific survival was defined as the time from
diagnosis to death if the patient died of breast cancer, or
to last known contact. Data for patients who died from
causes other than breast cancer, who missed follow-up or
for whom contact was interrupted, were censored. The
Kaplan–Meier method with a log-rank test was used to
establish the significance of genotypes of rs1271572 as
predictors of Survival Probability (SP). For the 631 women
with breast cancer, the same test was used to compare
differences between the different groups defined by the
G/T genotypes of rs1271572 (promoter of ERβ gene),
by their ERβ–positive and ERβ–negative status, their
ERα–positive and ERα–negative status, their HER2–
positive and HER2–negative status, or their PgR–positive
and PgR–negative status.
Cox proportional hazards models were used to test for
association of survival times of patients to their rs1271572
genotypes and to clinical characteristics, such as menopause,
age, tumor size, nodal status, breast cancer grade, and
ERα/HER2/PgR status. The 95% CI was used to quantify
the relationship between survival time and each independent
factor. All tests were 2-sided, and p values <0.05 were
considered to be statistically significant.Results and discussion
The rs1271572 G→ T genotype is associated with breast
cancer
As a negative regulator of ERα, ERβ plays a critical role
in breast cancer development. A number of common
polymorphisms have been identified in the ERβ gene
[11,12], with variable degrees of evidence of their direct
biological significance and their association with human
diseases [22-25]. A total of five SNPs in the promoter
region of the ERβ (ESR2) gene were selected (http://
www.ncbi.nlm.nih.gov/snp) as candidates for conferring
variations in all 1,518 patients (873 with breast cancer and
645 with breast fibroadenoma) and in the 700 healthy
blood donors. The tetra-primer ARMS-PCR method
was successfully applied to five different SNPs in the
promoter of the ERβ gene, i.e. the rs3020449 C→ T,
rs3020450 A→G, rs2987983 C→ T, rs1271572 G→ T
and rs1887994 G→ T polymorphisms. The genotypes
determined using this method were consistent with those
determined by the classical restriction endonuclease
digestion method [26].
Genotyping results for the selected 5 SNPs were
summarized in Additional file 4: Table S2. Specifically,
the frequencies of the genotypes for rs3020449, rs3020450
and rs1271572 were in Hardy-Weiberg equilibrium (http://
analysis.bio-x.cn/myAnalysis.php) (p > 0.05) in this set of
study population. No significant differences were observed
for the homozygous/heterozygous genotype frequencies of
SNPs rs3020449 and rs3020450 among the three groups. A
higher frequency of the homozygous TT genotype in
rs1271572 was observed in women with breast cancer
compared with those with fibroadenoma (p = 0.00019)
or healthy controls (p = 0.0008). There was no significant
difference in the TT genotype frequencies between the
fibroadenoma group and the blood donors group. In
addition, the genotype–phenotype association suggests
that the TT genotype of rs1271572 is a risk factor for
breast cancer development (cancer group vs. blood donors
group: Odds Ratio (OR) = 0.546, [95%CI 0.404–0.739],
χ2 = 15.54, p = 0.00008; and cancer group vs. fibroadenoma
group: OR = 0.558, [95%CI 0.409–0.759], χ2 = 13.89,
p = 0.00019).
The defect in PCR primer resulted in experimental failure
of the rs2987983. Indeed, the relationship between SNPs
in the promoter region and expression of ERbeta has
seldom been reported in China. Our studies are mainly
from a foreign population, which may cause rs1887994
selection failure. In addition, we did not do Bonferroni
adjustment, as only a few sites were analyzed.
Our analyses of the allelic frequencies of the five selected
ERβ SNPs in these study subjects revealed that women
with breast cancer more frequently carried the T allele of
SNP rs1271572 [cancer 45.03% vs. blood donors 38.35%,
OR = 1.310, 95% CI (1.060–1.619), χ2 = 6.27, p = 0.01229;
Figure 1 Results of ERβ staining in five consecutive trials. Human breast cancer sections immunostained for ERβ were subdivided using a
scoring system for ERβ expression into negative (no staining), weak (<20% staining), low (21–40% staining), medium (41–60% staining), and high
(>61% staining) expression. The percentage of sections in each expression level is indicated. The first two columns showed the results for all the
fibroadenoma (column 1) and breast cancer (column 2) sections. The last three columns showed the results for all breast cancer sections in each
of the genotypes of rs1271572.
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CI (1.072–1.654), χ2 = 6.69, p = 0.00969]. In contrast, no
significant difference in the allelic frequencies of SNPs
rs3020449 and rs3020450 were detected among the three
groups.
The SNPs in the promoter 0 N region of the ERβ gene
may affect breast cancer risk. Treeck provided evidence
that the CC genotype of rs2987983 could be a risk factor
for breast cancer development [8]. A recent report showedFigure 2 Immunohistochemical staining of ERβ in tissues from differe
immunostained for ERβ. A) All cells were negative for ERβ staining. B) Wea
staining). D) medium ERβ staining (41–60% cells were positive for ERβ stainthat homozygotes for the ERβ gene rs1271572/T are risk
factors for postmenopausal breast cancer treated with
hormone therapy [18]. The rs1271572 polymorphism is
also associated with prostate cancer risk among Chinese
men [20]. However, another study showed that none of
the SNPs in the ERβ gene promoter (including rs1271572)
were independently associated with breast cancer risk
[19]. Thus, the association of rs1271572 with breast
cancer remains controversial. But we reported that thent patients with breast cancer. Human breast cancer section were
k ERβ staining. C) Low ERβ staining (21–40% cells were positive for ERβ
ing), and high ERβ staining (>61% cells were positive for ERβ staining).
Table 1 Relationship between the genotypes of rs1271572 and ERβ status in Chinese patients with breast cancer
or fibroadenomas
Cancer patients, n (%) Fibroadenoma patients, n (%)
rs1271572 ERβ–positive ERβ–negative p value ERβ–positive ERβ–negative p value
GG 226 (26.43) 39 (4.56) 205 (32.64) 30 (4.78)
GT 350 (40.94) 60 (7.02) <0.001 266 (42.36) 38 (6.05) 0.93
TT 122 (14.27) 58 (6.78) 79 (12.58) 10 (1.59)
GG 226 (26.43) 39 (4.56) 205 (32.64) 30 (4.78)
GT+TT(T carrier) 472 (55.20) 118 (13.80) 0.07 345 (54.94) 48 (7.64) 0.901
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higher frequency in breast cancer patients than in fibro-
adenoma patients or in the blood donor control group
(p < 0.001), suggesting for the first time that the TT
genotype of rs1271572 in the ERβ gene promoter might
be an important risk factor for breast cancer in Chinese
women.
TT genotype of rs1271572 was associated with
downregulation of ERβ expression in breast cancer
As shown in Figure 1, no or weak staining for ERβ was
presented in less than 30% of fibroadenoma tissues,
whereas it was observed in nearly 40% of the breast cancer
tissues. Nearly 40% of the breast cancer tissues exhibited
either no staining or weak staining for ERβ compared
with < 30% for fibroadenoma tissues. Negative ERβ ex-
pression was more frequently observed in breast cancer
patients (18.36%) than that in the fibroadenoma group
(12.42%). Among the breast cancer patients with negative
ERβ expression, the proportion of patients carrying the
TT genotype (32.22%), was higher than that carrying
the GG (14.63%) and GT (14.72%) subgroups combined
(p < 0.05). Similarly, among breast cancer patients with
weak ERβ expression, the proportion of patients carrying
the TT genotypes of rs1271572 (31.78%) was higher than
for the other subgroups, GG (21.97%) and GT (20.22%)
(p < 0.05, Figure 1). Together, these results indicated that
in the breast cancer patients, the TT genotype of rs1271572
was strongly associated with negative or weak ERβ gene
expression. Expression of ERβ was determined usingTable 2 Relationship between the genotypes of rs1271572 and
patients
Groups Patients, n(%) GG
Cancer
ERβ–positive 698/855 (81.64) 226 /265 (8
Fibroadenoma
ERβ–positive 550/628 (87.58) 205/235 (8
OR 0.631 0.848
CI 95% 0.470–0.846 0.508–1.4
p value 0.002 0.528immunohistochemical staining. Representative staining
images with different scores were shown in Figure 2.
We also compared the genotype frequencies of
rs1271572 (GG, GT and TT) between the ERβ–positive
and ERβ–negative subgroups. The genotypes (GG, GT
and TT) of rs1271572 between the ERβ–positive and
ERβ–negative subgroups were found to be significantly
different in cancer patients (p < 0.001). Although frequen-
cies of the GG and GTcarrier was not significantly different
between the ERβ–positive and ERβ–negative subgroups
(p = 0.07), the frequency of TT genotype was significantly
lower (p < 0.001) than that of the other genotypes in
ERβ-positive patients. In breast fibroadenoma patients,
all genotypes and T carrier were similarly distributed
between ERβ–positive and ERβ–negative breast fibro-
adenoma patients (p = 0.930 and p = 0.901 respectively)
(Table 1).
We next analyzed the genotypic frequencies of rs1271572
in ERβ-positive cases between patients with breast cancer
and fibroadenoma. Although ERβ-positive cases were more
frequently detected in fibroadenoma patients (p = 0.002,
Table 2), ERβ-positive cases with rs1271572 TT genotype
was less frequently detected in breast cancer patients
(p < 0.001, Table 2). The genotypic frequencies of GT and
GG showed no significant difference between these two
subgroups.
Importantly, our results strongly suggest that the
TT genotype of rs1271572 may be associated with
downregulation of ERβ expression in breast cancer
(Figures 1 and 2, Tables 1 and 2).the ERβ–positive groups of breast cancer and fibroadenoma
GT TT
5.28) 350 /410 (85.37) 122/180 (67.78)




Table 3 Factors influencing the risk of death using
multivariate Cox regression analyses
Variable Hazard
ratio
95% CI Wald test
p value
Genotypes (TT v GT/GG) 2.58 1.31~ 3.79 0.0065
ERβ (negative v positive) 1.67 0.71~1.67 0.027
ERα (negative v positive) 0.81 0.67~0.98 0.035
HER2 (negative v positive) 1.78 0.76~1.87 0.015
Tumor size (<20 mm v ≥20 mm) 0.96 0. 62~1.51 0.951
Nodal status (positive v negative) 1.21 0.53~1.83 0.14
TNM (T3–4 v T1–2) 1.67 0.83~1.94 0.054
menopause (premenopausal v post) 1.26 1.03~1.78 0.058
age (≥50 v <50) 0.86 0.83~1.21 0.24
PgR(positive v negative) 0.97 0.76~1.09 0.21
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cancer-related death
Univariate and multivariate analyses were first performed
to examine whether rs1271572 genotypes were associated
with clinical parameters in breast cancer. No significantFigure 3 TT genotype of rs1271572 was associated with worse surviv
applied to determine the prognosis A) among patients with the three gen
ERβ–negative patients; C) between ERβ–negative and ERβ–positive patient
patients in the Her + patients. The p values were determined using the logassociation was observed between the frequency of either
the homozygous TT or heterozygous GT genotypes of
rs1271572 and the clinical characteristics including tumor
size, menopause, age, lymph node positive, breast cancer
related receptors status (ER-α, PgR, HER2) or breast
cancer stage (TNM) in patients with breast cancer
(Additional file 5: Table S3).
Multivariate Cox regression analyses were next
performed to explore whether rs1271572 genotypes
were associated with breast cancer susceptibility. As
shown in Table 3, the TT genotype of rs1271572
was an independent risk factor for cancer-related
death in breast cancer women (hazard ratio: 2.58;
95% CI: 1.31 ~ 3.79; p = 0.0065). Other statistically
significant variables associated with cancer-related
death included ERβ (hazard ratio: 1.67, p = 0.027),
ER-α (hazard ratio: 0.81, p = 0.035), and HER2 (hazard
ratio: 1.78, p = 0.015). Interestingly, the clinical tumor
size, nodal status, TNM, menopause, age and PgR
status did not show statistically significant associations
with cancer-related death in this cohort of breast cancer
patients.al in breast cancer. Kaplan–Meier breast cancer-free survival was
otypes (GG, GT and TT) of rs1271572; B) between ERβ–positive and
s in the ER- subgroup, and D) between ERβ–negative and ERβ–positive
-rank test; a significant difference was assumed for p < 0.05.
Table 4 The relationship of the genotypes of rs1271572 with the occurrence and location of distant metastases five
years following diagnosis
Recurrence Distant metastasis n (%)
rate n (%) Lung Liver Brain Bone Other
Breast cancer 218/835(26.11) 70/218(32.12) 42/218(19.27) 33/218(15.14) 52/218(23.85) 21/218(9.63)
GG 58/252(23.02) 20/58(34.48) 12/58(20.69) 6/58(10.34) 11/58(18.97) 9/58(15.52)
GT 95/404(23.51) 36/95(37.89) 17/95(17.89) 9/95(9.47) 26/95(27.37) 7/95(7.37)
TT 65/179(36.31) 15/65(23.08) 13/65(20.00) 19/65(29.23) 12/65(18.46) 6/65(9.23)
p value 0.065 0.231 0.904 0.005 0.835 0.483
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rs1271572, ERα and HER2, is an independent prognostic
factor for risk of cancer-related death in breast cancer
patients (Table 3). All these strongly suggest that TT
genotype of rs1271572 is a functionally important SNP
in breast cancer. Our finding that ERβ is related to a
favorable outcome is consistent with previous report by
of Vinayagam et al. [27].
TT genotype of rs1271572 was associated with poor
prognosis and higher risk of brain metastasis
The median follow up period was 43.24 (range 8.2–62.46)
months for the participated cancer patients, and the mean
follow up period was 49.33 months. The Kaplan-Meier
survival analyses demonstrated that patients with the TT
genotype of rs1271572 had a shorter survival rate than
patients with the GG or GT genotypes of rs1271572
(p < 0.001, Figure 3A). No significant difference in survival
rates between ERβ–positive and ERβ–negative patients
(p = 0.055, Figure 3B) was observed. However, among
ERα–negative and Her2-positive cases, ERβ–negative
patients had a shorter survival rate than ERβ–positive
patients (p = 0.015 and p < 0.001, respectively) (Figure 3C
and 3D). However, among ERα–positive and Her2-negative
cases, no correlations were observed between the
expression levels of ERβ and survival rates (data not
shown). In addition, we found that breast cancer patientsFigure 4 Prediction of TF binding sites in the different alleles of rs127
db/TFSEARCH.html) prediction of transcription factor binding sites in the ER
of the Yin Yang 1 (YY1) transcription factor binding site.with the TT genotype of rs1271572 were more likely
to suffer brain metastases (29.23%) than patients with the
GG (10.34%) or GT (9.47%) genotypes (p = 0.005)
(Table 4). The location of distant metastases was recorded
for the first metastatic organ found during the follow-up
period. Data for patients with multiple organ metastasis
first diagnosed during follow-up, were grouped in “other”
in Table 4.
Our results demonstrated that patients with the TT
genotype of rs1271572 had significantly poorer five-year
survival rates (Figure 3A) and were more likely to suffer
brain metastases (Table 4) than patients with the other
two genotypes. ERβ expression modulates adhesion and
migration of breast cancer cells [28], suggesting that the
TT genotype of rs1271572 might promote brain metastases
of breast cancer by suppressing ERβ gene expression.
Although there was no significant difference in cancer-
free survival between the ERβ–positive and ERβ–negative
subgroups (p = 0.055, Figure 3B) among breast cancer
patients, the TT homozygotes had poorer survival rates
(p < 0.001 Figure 3A). This apparent contradiction might
be because, in the TT genotype subgroup, patients with
both ERβ–negative and ERβ weak expression (nearly 64%)
were included. Moreover, ERβ–negative/ERα–negative
breast cancer patients had significantly poorer survival
rates compared with patients in the ERβ–positive/ERα–
negative subgroup (p = 0.015, Figure 3C). This result is1572. The results from the TFSEARCH (http://www.cbrc.jp/research/
β promoter were shown. The T allele of rs1271572 resulted in the loss
Figure 5 Binding of nuclear proteins in breast cancer cells to
32P- rs1271572G DNA probes. Different doses of nuclear proteins
isolated from MDA-MB-231 cells were incubated with 32P-rs1271572G
probes and the DNA-protein complexes were shown following
autoradiography (lanes 1–7). The nuclear proteins isolated from MCF-7,
MDA-MB-468, BT-549 and ZR75-30 were incubated with 32P -rs1271572G
and the DNA-protein complexes were shown (lane 9–12). When
32Prs1271572T probes were used, no specific DNA-protein binding was
observed (lanes 13 and 14). Binding activity of MDA-MB-231 nuclear
extracts with 32P-rs1271572G probe was inhibited by cold rs1271572G
probes(×50 times higher than 32P labeled probes) (lane 15). The
DNA-protein complex was supershifted after further incubating with
anti-YY1 antibody in MDA-MB-231 cells (lane 16). Position A indicated
the binding complex in the presence of the anti-YY1 antibody. Position
B indicated the binding complex of 32Prs1271572G DNA probes with
nuclear proteins from the different breast cell lines. Position C
indicated free 32P- rs1271572G DNA Probes.
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particularly in ERα–negative patients, was associated with
increased survival (distant disease-free survival) rates [29].
Rakha et al. recently reported that HER2+ was the poorest
prognostic factor among different molecular subtypes
[30]. In Her2 positive patients, ERβ–negative patients had
significantly poorer survival rates compared in the ERβ–
positive patients (p < 0.001, Figure 3D), suggesting that
ERβ–positivity confers a better outcome for patients with
the poor prognostic factors including ERα–negative and
HER2 –positive. All of the results reported here support
the finding that detection of ERβ status in breast cancer
tissues may provide clinically useful information in addition
to the well established ERα/HER2/PgR assay.
The rs1271572 T allele may be associated with loss of Yin
Yang 1 binding in ERβ promoter 0 N and suppress ERβ
expression in breast cancer
Transcription of the human ERβ gene occurs from at least
two different promoters, promoter 0 N and promoter 0 K,
with promoter 0 N being more prominent in breast
epithelial cells and breast cancer cells [15] [16]. As the TT
genotype of rs1271572 is significantly associated with low
ERβ expression in breast cancer patients (Figure 1), we
hypothesized that certain transcriptional factors (TFs) that
are critical to regulate ERβ expression specifically bind
to G allele, but not T allele containing promoters. To
search for TFs that differently bind to these pro-
moters, bioinformatics approaches (http://www.cbrc.jp/
research/db/TFSEARCH.html; http://variome.kobic.re.
kr/SNPatPromoter/) were used which showed that the
rs1271572 T allele could result in the loss of the Yin
Yang 1 (YY1) transcription factor binding (Figure 4).
We speculated that the loss of the YY1 binding site
might be involved in the decreased expression of the
ERβ gene.
To explore the role of the Tallele in YY1 binding, binding
activity of the two probes that contain sequence from
either rs1271572G or rs1271572T was compared using
EMSA in a panel of breast cancer cell lines. As shown in
Figure 5, specific protein-DNA complex were detected
with probe rs1271572G but not probe rs1271572T.
Moreover, supershift with YY1 antibody indicated that
YY1 was specifically bound to the rs1271572G oligo in
these cells. Our data have shown that except for YY-1,
other transcriptional factors could not bind to the region
of rs1271572G and that YY-1 lost its capacity to bind to
the region of rs1271572(T) (Figure 5).
To further determine whether the T allele of rs1271572
confers decreased transcriptional activity of the ERβ gene
promoter, we compared the luciferase reporter activity of
pESR2-0 N-G-Luc and pESR2-0 N-T-Luc. Indeed, the
reporter activity of pESR2-0 N-T-Luc was significantly
lower that of pESR2-0 N-G-Luc, (Figure 6A and 6B),suggesting that the T allele of rs1271572 could lead to a
decrease in the transcription activity of the ERβ gene
promoter 0 N. In agreement with a previous report that
transcripts from promoter 0 N were more prominent than
those from promoter 0 K [16], we also observed that the lu-
ciferase activity of pESR2-0 K-Luc was significantly weaker
than that of pESR2-0 N-G-Luc in the five breast cancer cell
lines and in the primary cancer cells of two patients. Inter-
estingly, luciferase activity of pESR2-0 N-G-Luc but not
pESR2-0 N-T-Luc was dramatically decreased in these cells
when co-transfected with YY1-specific siRNA oligos along
with pESR2-0 N-G-Luc, pESR2-0 N-T-Luc or pESR2-0
K-Luc, indicating that YY1 is involved in regulation of the
activity of ERβ gene promoter 0 N (Figure 6A and 6B).
Figure 6 The T allele of rs1271572 down-regulated the activity of the ERβ promoter 0 N.A). The human breast cancer cells (MDA-MB-231,
MCF-7, MDA-MB-468, BT-549 and ZR75-30) were transfected with the normalization control vector pRL and each of the pESR2-0 N-G-Luc, pESR2-0
N-T-Luc, pESR2-0 K-Luc (promoter 0 K) alone, or together with the YY1-specific siRNA oligos. Lucifease activities of these reporters were
determined using the dual luciferase assay kit. B). Primary breast cancer cells (N1, N2 and N3) were transfected with the vectors as in A) and luciferase
activity was determined. The figure represents the results of three independent experiments. *p <0.05;**p <0.01. Graphs show means + −S.E.M. (n =8).
C). The human breast cancer cell lines (MDA-MB-231, MCF-7, MDAMB468, BT549 and ZR75-30) and the primary breast cancer cells (N1 and N2) were
transfected with YY1-specific siRNA oligos and YY1 expression was examined by western blot. β-actin was used to confirm equal protein loading. Each
lane was loaded with up to 30 μg of protein.
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of rs1271572 was associated with low ERβ expression
(Figure 1). The in vitro luciferase assays showed that the
rs1271572 G→T allele could reduce the transcription
activity of promoter 0 N in ERβ gene expression (Figure 6A
and 6B). These results suggest that the rs1271572 G→T
allele is associated with the inhibition of expression of the
ERβ gene in patients with breast cancer. Bioinformatics
tools predicted that the rs1271572 G→T allele led to the
loss of binding of the YY1 transcription factor (Figure 4).
Yin Yang 1 (YY1) transcription factor is highly expressed
in various types of cancers and regulates tumorigenesis
through multiple pathways. YY1 is generally overexpressedin breast cancer cells and tissues, and YY1 is an oncogene
which negatively regulates p27. [31]. YY1 is a multifunc-
tional protein that plays a fundamental role in normal
biological processes such as embryogenesis, differentiation,
replication, and cellular proliferation in vertebrates [32,33].
The reduction of inhibition of YY1 expression promoted
cell migration and resulted in an invasive phenotype in
breast cancer cells [34]. Pathway meta-analyses identified a
number of important factors, including the YY1 transcrip-
tion factor that were implicated in the metastasis of breast
cancer [35]. We thus hypothesized that the TT genotype of
rs1271572 suppressed ERβ expression by inhibiting YY1
binding. In support of this hypothesis, no DNA-protein
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sequence from rs1271572T region (Figure 5). Moreover,
knockdown of YY1 in breast cancer cells lines and
primary breast cancer cultures also decreased the
transcriptional activity of the promoter 0 N (Figure 6).
Further mechanistic studies will be needed to identify
additional key factors through which rs1271572 TT
regulate the expression of ERβ expression in breast cancer.
Conclusion
In this study we report that Chinese women with the TT
genotype of rs1271572 had a significantly higher risk of
breast cancer and have a poor prognosis and were more
likely to suffer brain metastasis. The homozygous TT
genotype of rs1271572 was associated with low ERβ
expression in breast cancer patients. Further mechanistic
studies revealed that TT genotype of rs1271572 resulted in
loss of the YY1 binding site and reduced the transcription
activity of the promoter 0 N in the ERβ gene.
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